By Will Feuer

 

Zoetis Inc. cut its full-year adjusted earnings guidance and lowered the high-end of its range for sales, citing negative effects from recent changes to foreign-exchange rates.

The animal-medicine company, spun off by Pfizer Inc. in 2013, said it now expects adjusted earnings of between $4.97 a share and $5.05 a share, down from its prior guidance of $4.99 a share to $5.09 a share.

Full-year revenue is expected to be between $8.225 billion and $8.325 billion, narrowed from $8.225 billion to $8.375 billion. Unadjusted earnings are expected to be between $4.65 a share and $4.75 a share, narrowed from a range of $4.65 a share to $4.77 a share.

 

Write to Will Feuer at Will.Feuer@wsj.com

 

(END) Dow Jones Newswires

August 04, 2022 07:51 ET (11:51 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
Von Aug 2022 bis Sep 2022 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
Von Sep 2021 bis Sep 2022 Click Here for more Pfizer Charts.